Sensex gains 204 pts; pharma shares in demand

Image
Last Updated : Aug 30 2024 | 11:04 AM IST
The domestic equity benchmarks traded with moderate gains in morning trade. The Nifty traded above the 25,200 level. Pharma shares advanced after declining in the previous trading session.

At 10:30 IST, the barometer index, the S&P BSE Sensex gained 204.15 points or 0.25% to 82,338.76. The Nifty 50 index added 65.85 points or 0.26% to 25,217.80.

The Sensex and Nifty clocked an all-time high of 82,637.03 and 25,258.80, respectively in early trade.

In the broader market, the S&P BSE Mid-Cap index rose 0.55% and the S&P BSE Small-Cap index gained 0.36%.

The market breadth was positive. On the BSE, 2,107 shares rose and 1,483 shares fell. A total of 160 shares were unchanged.

Buzzing Index:

The Nifty Pharma index gained 1.14% to 23,138.20. The index shed 0.48% in the past trading session.

Natco Pharma (up 3.72%), Divis Laboratories (up 1.88%), Ipca Laboratories (up 1.86%), Biocon (up 1.60%), Lupin (up 1.45%), Alkem Laboratories (up 1.33%), Zydus Lifesciences (up 1.32%), Torrent Pharmaceuticals (up 1.3%), Granules India (up 1.24%) and Cipla (up 1.24%) advanced.

Stocks in Spotlight:

ITI advanced 2.37% after the company has received the orders from State Election Commission (SEC) of West Bengal for the supply of 500 sets of electronic voting machines (EVM).

Poonawalla Fincorp declined 1.01%. The company informed that its board has approved the appointment of Bhaskar Pandey as the new Chief Risk Officer (CRO) of the company, for a tenure of 5 years.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 30 2024 | 10:36 AM IST

Next Story